PMID- 38461536
OWN - NLM
STAT- Publisher
LR  - 20240310
IS  - 2831-090X (Electronic)
IS  - 2831-0896 (Linking)
DP  - 2024 Mar 10
TI  - Echinacoside ameliorates hepatic fibrosis and tumor invasion in rats with 
      thioacetamide-induced hepatocellular carcinoma.
LID - 10.17305/bb.2024.10367 [doi]
AB  - Hepatocellular carcinoma (HCC) affects approximately 800,000 individuals globally 
      each year. Despite advancements in HCC treatments, there is still a pressing need 
      to identify new drugs that can combat resistance. One potential option is 
      echinacoside, a natural caffeic acid glycoside with antioxidant, 
      anti-inflammatory, antidepressant, and antidiabetic properties. Therefore, we 
      aimed to investigate the ability of echinacoside to exhibit antitumor activity 
      against HCC in rats through ameliorating hepatic fibrosis and tumor invasion. 
      Rats were given thioacetamide to induce HCC, and some were given 30 mg/kg of 
      echinacoside twice a week for 16 weeks. The liver impairment was assessed by 
      measuring serum alpha-fetoprotein (AFP) and examining liver sections stained with 
      Masson trichrome or anti-transforming growth factor (TGF)-beta1 antibodies. The 
      hepatic expression of mRNA and protein levels of TGF-beta1, beta-catenin, SMAD4, matrix 
      metalloproteinase-9 (MMP9), phosphoinositide 3-kinases (PI3K), mammalian target 
      of rapamycin (mTOR), connective tissue growth factor 2 (CCN2), E-Cadherin, 
      platelets derived growth factor (PDGF)-B and fascin were also analyzed. 
      Echinacoside improved the survival rate of rats by decreasing serum AFP and the 
      number of hepatic nodules. Examination of micro-images indicated that 
      echinacoside can reduce fibrosis. It also significantly decreased the expression 
      of TGF-beta1, beta-catenin, SMAD4, MMP9, PI3K, mTOR, CCN2, PDGF-B, and fascin while 
      enhancing the expression of E-Cadherin. In conclusion, echinacoside exhibits a 
      protective effect against HCC by increasing survival rates and decreasing tumor 
      growth. It also acts as an inhibitor of the hepatic tissue fibrosis pathway by 
      reducing the expression of TGF-beta1, beta-catenin, SMAD4, PI3K, CCN2, PDGF-B and mTOR. 
      Additionally, it prevents tumor invasion by suppressing MMP9 and fascin, and 
      increasing the expression of E-Cadherin.
FAU - Albalawi, Ajwan Z
AU  - Albalawi AZ
AD  - PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
FAU - Alatawi, Areej S
AU  - Alatawi AS
AD  - PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
FAU - Al-Atwi, Shekha M
AU  - Al-Atwi SM
AD  - PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
FAU - Alhwyty, Lama S
AU  - Alhwyty LS
AD  - PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
FAU - Alharbi, Kadi M
AU  - Alharbi KM
AD  - PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
FAU - Alshehri, Shahad A
AU  - Alshehri SA
AD  - PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
FAU - Almarwani, Wasayf A
AU  - Almarwani WA
AD  - PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
FAU - Aljohani, Khulud K
AU  - Aljohani KK
AD  - PharmD Program, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
FAU - Hassan, Hanan M
AU  - Hassan HM
AD  - Department of Pharmacology and Biochemistry, Faculty of Pharmacy, Delta 
      University for Science and Technology, Gamasa City, Egypt.
FAU - Al-Gayyar, Mohammed M H
AU  - Al-Gayyar MMH
AD  - Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 
      Egypt; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of 
      Tabuk, Tabuk, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20240310
PL  - Bosnia and Herzegovina
TA  - Biomol Biomed
JT  - Biomolecules & biomedicine
JID - 9918522188506676
SB  - IM
EDAT- 2024/03/10 18:42
MHDA- 2024/03/10 18:42
CRDT- 2024/03/10 16:12
PHST- 2024/02/12 00:00 [received]
PHST- 2024/03/06 00:00 [accepted]
PHST- 2024/03/10 18:42 [medline]
PHST- 2024/03/10 18:42 [pubmed]
PHST- 2024/03/10 16:12 [entrez]
AID - 10.17305/bb.2024.10367 [doi]
PST - aheadofprint
SO  - Biomol Biomed. 2024 Mar 10. doi: 10.17305/bb.2024.10367.